Meet Our Team of Specialists
Board-certified specialists provide state-of-the-art diagnosis and treatment at one convenient location in Boston's Longwood medical area. By working in tandem with referring physicians, we can help patients understand their condition, the diagnostic tests they need, their surgical procedure, post-op instructions and follow-up.
David F. McDermott, MD, is Co-Director of the Renal Tumor Program. He is Clinical Director of the Biologic Therapy Program, nationally recognized for its contributions to the biologic treatment of cancer using cytokines, vaccines and other novel agents. Dr. McDermott graduated from Amherst College and Cornell University Medical College. He completed his residency training in Internal Medicine and fellowship in Hematology/Oncology at Tufts/New England Medical Center. As clinical investigator in oncology at BIDMC, Dr. McDermott focuses on the treatment of renal cell carcinoma and melanoma. Dr. McDermott was co-investigator and lead author for the Phase III randomized trial of High-Dose Interleukin-2 versus Interleukin-2/Interferon in patients with metastatic renal cell carcinoma. He is principal investigator for ECOG protocol 2803, a phase II trial of carboplatin and taxol in patients with metastatic collecting duct tumors. He is also co-chair for ECOG 2804, a multi-arm randomized phase II of targeted therapy in metastatic renal cell carcinoma. Dr. McDermott is currently developing a randomized phase II trial that aims to explore methods of overcoming resistance in patients who are treated with VEGFR TKIs.
Andrew A. Wagner, MD, is Co-Director of the Renal Tumor Program. He is Director of Minimally Invasive Urologic Surgery. Dr. Wagner graduated from Boston University’s College of Engineering and SUNY at Buffalo, School of Medicine and Biomedical Sciences. He completed his urology residency at the University of Massachusetts Hospital in Worcester, and went on to complete a fellowship in laparoscopy and minimally invasive urologic surgery at the Brady Urologic Institute at Johns Hopkins University in Baltimore. Dr. Wagner’s primary clinical interest includes minimally invasive urology, focusing on laparoscopic and percutaneous treatment of renal tumors and laparoscopic treatment of benign kidney diseases (e.g. ureteropelvic junction obstruction, renal cyst ablation). He belongs to the American Urological Association and Endourological Society.
William C. DeWolf, MD, FACS, is Professor of Surgery at Harvard Medical School, Urologist-in-Chief at Beth Israel Deaconess Medical Center, and Director of the Urologic Research Laboratories. He received his BS and MD degrees from Northwestern University. Following a surgical internship and residency at Presbyterian St. Luke’s Hospital in Chicago, Dr. DeWolf completed additional training in General Surgery and Transplantation. His research focuses on molecular genetics, developmental biology and biochemistry of malignancy. Over the years, Dr. DeWolf has received major awards from the National Institute of Health, American Urologic Association; and on three separate occasions, the Harvard Program in Urology. In addition to presiding over the National Urologic Forum (2001-2002), he belongs to such organizations as the Society for Basic Urologic Research, American Association for Cancer Research and American Society of Genitourinary Surgeons. Dr. DeWolf also serves on the editorial board of Urology.
Michael B. Atkins, MD, is a graduate of Tufts University and Tufts Medical School and completed a residency in medicine and a fellow
ship in hematology/oncology at New England Medical Center. After 10 years on staff at NEMC he joined the staff of the Division of Hematology/Oncology at Beth Israel Deaconess Medical Center (BIDMC) in 1997 and was appointed Deputy Chief of this Division in 2002 and Professor of Medicine at Harvard in 2003. His research focuses on clinical and translational investigations in melanoma and renal cancer with a particular emphasis on cytokine-based immunotherapy and antiangiogenic therapy. He is currently Director of the Cutaneous Oncology and Biological Therapy Programs at BIDMC and also directs the BIDMC Cancer Clinical Trials Office. He has served on various committees and professional societies including the ASCO and AACR Program Committees, the Medical Advisory Boards for the Kidney Cancer Association, Melanoma Research Foundation and the Melanoma Foundation of New England and is past-President of the International Society for Biological Therapy of Cancer. Dr. Atkins is also the leader of the Kidney Cancer Program at the Dana-Farber Harvard Cancer Center (DF/HCC) and Director of the DF/HCC Kidney Cancer SPORE grant and Co-Principal Investigator of the DF/HCC Skin Cancer SPORE Grant. He has published over 200 articles and chapters on melanoma, renal cancer, and biological therapy of cancer. He has co-edited two textbooks entitled Interleukin 2 published in 1993 and Clinical Practice of Hematology and Oncology: Presentation, Diagnosis and Treatment published in 2003.
S. Nahum Goldberg, MD, is Associate Professor in Radiology at Harvard Medical School and Staff Radiologist at Beth Israel Deaconess Medical Center. He is also Director of the Abdominal Intervention and Tumor Ablation Therapy Program and Minimally Invasive Tumor Therapy Laboratory. Dr Goldberg graduated from Yeshiva University in New York and Yale School of Medicine. He completed his residency in diagnostic radiology with a clinical fellowship in abdominal imaging and interventional radiology at Massachusetts General Hospital. Dr. Goldberg’s research focuses on the development of image-guided, minimally invasive oncologic therapies such as radiofrequency ablation, used in combination with biologic modulators, chemotherapy and radiation. Dr. Goldberg belongs to the National Hyperthermia and Thermal Therapy Society, Radiologic Society of North America and Society for Interventional Radiology, to name a few.
Irving Kaplan, MD is Assistant Professor at the Joint Center for Radiation Oncology at Harvard Medical School and Staff Radiation
Oncologist at Beth Israel Deaconess Medical Center. He graduated from University of Rochester (Magna Cum Laude) and Stanford University School of Medicine. Following an internship at the Kaiser Foundation Hospital in Santa Clara, Dr. Kaplan returned to Stanford for a residency in radiation oncology. Major research interests include prostate cancer: radiation therapy and Prostrate-Specific Antigen as a marker of response, and treatment of lung cancer. Dr. Kaplan’s honors include the American Cancer Society Clinical Fellowship and Robert D. Moseley, Jr. Award in Radiation Protection in Medicine.
Ivan Pedrosa, MD, is Assistant Professor in Radiology at Harvard Medical School and Staff Radiologist in the Abdominal/MRI section at Beth Israel Deaconess Medical Center. Dr. Pedrosa graduated from Universidad Complutense de Mad
rid, Spain. He completed his residency in radiology at Hospital Clinico San Carlos, Madrid. Dr. Pedrosa completed fellowships in trauma/emergency radiology at University of Miami School of Medicine and body MR imaging at BIDMC. In 2005, Dr Pedrosa was awarded “Best Teacher of the Year” in the Department of Radiology at BIDMC. In 2006, Dr Pedrosa won the Joseph E. and Nancy O. Whitley Award for the best manuscript on a subject related to radiology education. He belongs to the Radiological Society of North America, International Society of Magnetic Resonance in Medicine and the Spanish Society of Radiology. Additionally, Dr. Pedrosa is a reviewer for Radiology and American Journal of Roentgenology.
Neil Rofsky, MD, is Associate Professor of Radiology at Harvard Medical School and Director of Magnetic Resonance Imaging a
t Beth Israel Deaconess Medical Center. Dr. Rofsky attended New York Medical College in Valhalla, NY and completed his residency in radiology at NYU Medical Center with fellowships in nuclear medicine, abdominal imaging, and magnetic resonance imaging. In addition to research programs in renal tumor imaging and prostate cancer imaging, Dr. Rofsky has well developed programs that use MRI for the assessment of tissue and tumor perfusion. He is the co-director of the Monitoring Core of the Renal Cancer SPORE at DF/HCC. His teaching activities include the creation of self-learning modules accessible to residents via the intranet. In 2005, Dr. Rofsky received the Lauterber Award for an “Outstanding Scientific Paper on Cross Sectional Imaging” and a Developmental Project Award from the National Cancer Institute for “Arterial Spin Labeling for RCC." He belongs to the Radiological Society of North America, American College of Radiology, International Society of Magnetic Resonance Imaging and is a reviewer for Radiology, Journal of Magnetic Resonance Imaging and New England Journal of Medicine.
